Risk of Endo's opioid painkiller outweigh benefits: FDA panel

(Reuters) - The benefits of Endo International Plc's long-acting opioid painkiller no longer outweigh its risks, an independent panel to the U.S. Food and Drug Administration concluded on Tuesday.